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Abstract
Extranodal lymphoma, secondary to or accompanying nodal disease is uncommon, but not unusual finding. 18-Fluorodeoxyglu-
cose positron emission tomography (18F-FDG PET/CT) imaging has an essential role in the staging of lymphoma, in treatment 
response monitoring, and in detection of recurrence. We present a case of a 52-year-old man with generalized diffuse large 
B-cell lymphoma (DLBCL) with multiple extranodal sites involvement detected by 18F-FDG PET/CT. With this clinical case we 
demonstrate that 18F-FDG PET-CT is a more effective technique than CE-CT for the evaluation of viable extranodal involvement 
of the diffuse large B-cell lymphoma (DLBCL) and should be combined in the monitoring of DLBCL.
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Background
Diffuse large B-cell lymphoma (DLBCL) is the most common 
form of NHL. It can arise in lymph nodes or outside of the lym-
phatic system, in the gastrointestinal tract, testes, thyroid, skin, 
breast, bone, or brain. The involvement of specific extranodal 
sites has shown a prognostic value in the rituximab era. The ex-
tranodal involvement of the lung/pleura, liver, lower urinary tract or 
bone marrow was a statistically significant poor prognostic factor. 
In multivariate analysis, specific extranodal sites had a stronger 
predictive value for poor prognosis, compared with the number 
of extranodal sites involved [1]. Lung/pleural involvement is a very 
rare condition among B-cell lymphomas since it mainly occurs in 
the setting of a generalized disease. Of 854 patients affected by 
B-cell lymphoma, 7.5% had lung/pleural disease, a secondary 
involvement was registered in 6.8%. Most of them were affected 
by DLBC (8%) followed by follicular lymphoma [2].
Renal parenchymal involvement is uncommon in DLBCL. In 
almost all cases, renal involvement appears to be a secondary 
process, either by direct extension from a retroperitoneal mass or 
via hematogenous spread in the setting of disseminated disease 
[3]. Retrospective cohort studies reveal that these patients tend 
to present with widespread disease and have a poor outcome in 
part due to a high rate of central nervous system (CNS) relapse. 
A recently published report from the British Columbia Cancer 
Agency showed that kidney involvement is an independent risk 
factor for CNS relapse in patients with DLBCL in both the pre- and 
post-rituximab treatment eras [4].
Case report
We present a case of a 52-year-old man with generalized 
disease with multiple extranodal sites involvement. The patient 
was first admitted to the hospital in August 2011 with right chest 
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pain, dyspnea, night sweats. The physical examination and CT 
revealed a generalized lymphadenomegaly and pleural effusion. 
A biopsy of a supraclavicular lymph node revealed a follicular NHL 
(Figures 1, 2).
The stage was determined IVB because of bone marrow 
involvement. The patient was considered intermediate risk accord-
ing to Follicular Lymphoma International Prognostic Index (FLIPI). 
From September 2011 the patient received 4 courses of R-CHOP. 
Because of disease progression a biopsy was performed and 
revealed transformation into DLBCL. Untill July 2013 the patient 
received 5 courses of R-MINE, 4 courses of FMD, and 6 R-ESHAP. 
In July 2013 a complete response was achieved determined by 
PET/CT (Figure 3). 
A year later the patient presented with a back pain and night 
sweats. MRI was performed (protocol SAG T1, SAG STIR, COR 
T2, AX T2). It revealed a huge, isointense parenchymal lesion, 
adjacent to the chest wall in the left apical region. Cranially, the 
lesion infiltrated the soft tissues between the ribs and the apical 
fatty tissue. Medially, there was also infiltration of the neuroforamina 
at the level of Th5–Th6, and the mass was projecting into the 
spinal channel. A second, smaller lesion was fond on the right, 
paravertebral (Figure 4). Biological clarification of the lesions’ 
activity was needed.
The 18F-FDG PET/CT (performed as a low-dose CT from vertex 
to mid-thigh and PET with a corresponding field, on a Phillips Gemini 
TF PET/CT after intravenous administration of 0.13 mCi/kg FDG PET 
and 60-minute uptake period) revealed a huge parenchymal lesion, 
adjacent to the chest wall in the left apical region with increased 
uptake of 18F-FDG with SUV max 8.6 (Figure 5A). Another soft tissue 
lesion at the upper pole of the right kidney was seen with increase 
SUV max 4.1 as well as PET positive common iliac lymph nodes at 
the right side with SUV max 6.0 (Figure 5B), solitary inguinal lymph 
node at the left side with SUVmax 4.4 and bone marrow involvement 
of Th8 and Th9 with SUVmax 3.0. PET hypermetabolic lesions in 
lung and in right kidney were verified histopathologically as a true 
positive extranodal relapse of diffuse large B-cell lymphoma after 
the true cut biopsy (Figure 6).
Conclusions
Extranodal lymphoma, secondary to or accompanying nodal 
disease is uncommon, but not unusual finding. 18F-FDG PET/CT 
imaging has an essential role in the staging of lymphoma, in treat-
ment response monitoring and in detection of recurrence. 18F-FDG 
PET-CT is a more effective technique than CE-CT for the evaluation 
of extranodal involvement in Hodgkin and non-Hodgkin lymphoma 
Figure 1. Lymph node, HE, 10 × 10, diffuse effacement of the 
architecture — lymphoma
Figure 2. Lymph node, HE, 10 × 20, diffuse proliferation of atypical 
lymphocytes — lymphoma
Figure 3. 18F-FDG PET/CT reveals complete remission of the disease. 
There is no pathological hypermetabolic lesion throughout the 
patient’s body
Figure 4A. Axial T2 WI demonstrates the mass projecting through 
the neuroforamina; B. COR T2 WI shows the left apical mass and 
the smaller right-sided paravertebral lesion; C. SAG STIR — the 
paravertebral mass with hyperintensity; D. SAG T1 WI — the lesion is 
depicted as a hypointense and infiltration of the soft tissues
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patients. PET-CT has a significant advantage for the diagnosis of 
diffusely infiltrating organs without mass lesions or contrast en-
hancement compared to CE-CT [5]. As a hybrid imaging modality 
it allows accurate localization of disease and may be beneficial 
for the detection of unexpected extranodal sites of disease or 
exclusion of disease in the presence of nonspecific or equivocal 
extranodal CT findings.
Figure 5A. Coronal, sagittal and transaxial 18F-FDG PET/CT scans 
reveals a huge isointense parenchymal lesion, adjacent to the 
chest wall in the left apical region (SUV max 8.6); B. 
18F-FDG PET/CT 
scan with a hypermetabolic, parenchymal lesion in the right kidney 
confirmed as an extranodal relapse of DLBCL
Figure 6A. True cut biopsy from lung, HE, 10 × 20, diffuse infiltration 
of atypical cells; B. True cut biopsy from lung, IHC,10 × 20, 
membrane expression of CD20
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